Department EMbeDS, Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy.
Eur J Health Econ. 2023 Mar;24(2):169-177. doi: 10.1007/s10198-022-01462-w. Epub 2022 May 5.
This study aimed to estimate healthcare costs of diabetic foot disease (DFD) in a large population-based cohort of people with type-2 diabetes (T2D) in the Tuscany region (Italy).
DATA SOURCES/STUDY SETTING: Administrative healthcare data of Tuscany region, with 2018 as the base year.
Retrospective study assessing a longitudinal cohort of patients with T2D.
DATA COLLECTION/EXTRACTION METHODS: Using administrative healthcare data, DFD were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification codes.
We examined the annual healthcare costs of these clinical problems in patients with T2D between 2015 and 2018; moreover, we used a generalized linear model to estimate the total healthcare costs.
Between 2015 and 2018, patients with T2D experiencing DFD showed significantly higher average direct costs than patients with T2D without DFD (p < 0.0001). Among patients with T2D experiencing DFD, those who experienced complications either in 2015-2017 and in 2018 incurred the highest incremental costs (incremental cost of € 16,702) followed by those with complications in 2018 only (incremental cost of € 9,536) and from 2015 to 2017 (incremental cost of € 800).
DFD significantly increase healthcare utilization and costs among patients with TD2. Healthcare costs of DFD among patients with T2D are associated with the timing and frequency of DFD. These findings should increase awareness among policymakers regarding resource reallocation toward preventive strategies among patients with T2D.
本研究旨在估计 2 型糖尿病(T2D)患者大型人群队列中糖尿病足病(DFD)的医疗保健费用。
数据来源/研究设置:以 2018 年为基础年的托斯卡纳地区行政医疗保健数据。
回顾性研究评估 T2D 患者的纵向队列。
数据收集/提取方法:使用行政医疗保健数据,使用国际疾病分类,第九修订版,临床修正代码识别 DFD。
我们检查了 2015 年至 2018 年期间 T2D 患者这些临床问题的年度医疗保健费用;此外,我们使用广义线性模型来估计总医疗保健费用。
在 2015 年至 2018 年间,患有 DFD 的 T2D 患者的平均直接成本明显高于没有 DFD 的 T2D 患者(p <0.0001)。在患有 DFD 的 T2D 患者中,那些在 2015-2017 年和 2018 年经历并发症的患者的增量成本最高(增量成本为€16702),其次是仅在 2018 年经历并发症的患者(增量成本为€9536)和从 2015 年到 2017 年(增量成本为€800)。
DFD 显著增加了 T2D 患者的医疗保健利用和成本。T2D 患者 DFD 的医疗保健费用与 DFD 的时间和频率有关。这些发现应提高决策者对 T2D 患者预防策略的资源重新分配的认识。